Tandem Diabetes (TNDM) Care announced publication by The New England Journal of Medicine of results from the company’s pivotal trial of Control-IQ+ automated insulin delivery technology in people with ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Hosted on MSN
Tandem Diabetes Care highlights potential for type 2 diabetes market growth with Control-IQ+
CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...
GlobalData on MSN
FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback